Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT1 | Q96EB6 | 8/20 | 0.52 |
| ▸ | HTR1B | P28222 | 5/20 | 0.45 |
| ▸ | HTR1D | P28221 | 4/20 | 0.45 |
| ▸ | SIRT2 | Q8IXJ6 | 3/20 | 0.43 |
| ▸ | SIRT3 | Q9NTG7 | 2/20 | 0.43 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.43 |
| ▸ | VPS4B | O75351 | 1/20 | 0.43 |
| ▸ | VCP | P55072 | 1/20 | 0.43 |
| ▸ | NR2E1 | Q9Y466 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 2/20 | 0.42 |
| ▸ | HTR2C | P28335 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4900711 | 0.84 | VPS4B (0.58) | HTR1BHTR1DVPS4BVCPHTR2A | |
| SCHEMBL4900652 | 0.84 | VPS4B (0.58) | HTR1BHTR1DVPS4BVCPHTR2A | |
| SCHEMBL4895828 | 0.83 | HTR1B (0.39) | SIRT1HTR1BHTR1DVPS4BVCP | |
| SCHEMBL6529419 | 0.82 | HTR1B (0.65) | SIRT1HTR1BHTR1DSIRT2SIRT3 | |
| SCHEMBL6529421 | 0.82 | HTR1B (0.65) | SIRT1HTR1BHTR1DSIRT2SIRT3 | |
| SCHEMBL10748232 | 0.80 | NR2E1 (0.66) | NR2E1HTR2AHTR2C | |
| SCHEMBL4904688 | 0.79 | VPS4B (0.39) | HTR1BHTR1DVPS4BVCPNR2E1 | |
| SCHEMBL23657201 | 0.79 | KMT2A (0.64) | SIRT1HTR1BHTR1DBAZ2BHTR2A | |
| SCHEMBL7409510 | 0.79 | SIRT1 (0.55) | SIRT1HTR1BHTR1DSIRT2SIRT3 | |
| SCHEMBL4902694 | 0.78 | HTR1B (0.51) | HTR1BHTR1DVPS4BVCPKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080081910-A1 | CYCLOALKYLFUSED INDOLE, BENZOTHIOPHENE, BENZOFURAN AND INDENE DERIVATIVES | WYETH (US) | 2008-04-03 | — | — | US | claimed |
| EP-1856126-A2 | CYCLOALKYLFUSED INDOLE, BENZOTHIOPHENE, BENZOFURAN AND INDENE DERIVATIVES | Wyeth a Corporation of the State of Delaware (US) | 2007-11-21 | — | — | EP | claimed |
| US-20060205759-A1 | Cycloalkylfused indole, benzothiophene, benzofuran and indene derivatives | WYETH (US) | 2006-09-14 | — | — | US | claimed |
| WO-2006089053-A2 | CYCLOALKYLFUSED INDOLE, BENZOTHIOPHENE, BENZOFURAN AND INDENE DERIVATIVES | WYETH (US) | 2006-08-24 | — | — | WO | claimed |
| US-12583818-B2 | Compound, preparation method thereof, and use thereof | DAEGU-GYEONGBUK MEDICAL INNOVATION FOUNDATION (KR) | 2026-03-24 | — | — | US | disclosed |
| EP-4065553-B1 | NOVEL COMPOUND, PREPARATION METHOD THEREOF, AND USE THEREOF | DAEGU GYEONGBUK MEDICAL INNOVATION FOUND (KR) | 2025-01-29 | — | — | EP | disclosed |
| CN-114981241-B | Novel compounds, process for their preparation and their use | 大邱庆北尖端医疗产业振兴财团 | 2024-11-19 | — | — | CN | disclosed |
| US-20230142654-A1 | NOVEL COMPOUND, PREPARATION METHOD THEREOF, AND USE THEREOF | PIMEDBIO, INC. (KR) | 2023-05-11 | — | — | US | disclosed |
| US-20230142654-A1 | NOVEL COMPOUND, PREPARATION METHOD THEREOF, AND USE THEREOF | PIMEDBIO, INC. (KR) | 2023-05-11 | — | — | US | disclosed |
| US-20230142654-A1 | NOVEL COMPOUND, PREPARATION METHOD THEREOF, AND USE THEREOF | PIMEDBIO, INC. (KR) | 2023-05-11 | — | — | US | disclosed |
| EP-4065553-A1 | NOVEL COMPOUND, PREPARATION METHOD THEREOF, AND USE THEREOF | Daegu-Gyeongbuk Medical Innovation Foundation (KR) | 2022-10-05 | — | — | EP | disclosed |
| CN-114981241-A | Novel compound, preparation method and application thereof | 大邱庆北尖端医疗产业振兴财团 | 2022-08-30 | — | — | CN | disclosed |
| WO-2021145729-A1 | NOVEL COMPOUND, PREPARATION METHOD THEREOF, AND USE THEREOF | DAEGU-GYEONGBUK MEDICAL INNOVATION FOUNDATION (KR) | 2021-07-22 | — | — | WO | disclosed |
| WO-2021145729-A1 | NOVEL COMPOUND, PREPARATION METHOD THEREOF, AND USE THEREOF | DAEGU-GYEONGBUK MEDICAL INNOVATION FOUNDATION (KR) | 2021-07-22 | — | — | WO | disclosed |
| US-20080081910-A1 | CYCLOALKYLFUSED INDOLE, BENZOTHIOPHENE, BENZOFURAN AND INDENE DERIVATIVES | WYETH (US) | 2008-04-03 | — | — | US | disclosed |
| EP-1856126-A2 | CYCLOALKYLFUSED INDOLE, BENZOTHIOPHENE, BENZOFURAN AND INDENE DERIVATIVES | Wyeth a Corporation of the State of Delaware (US) | 2007-11-21 | — | — | EP | disclosed |
| US-7297704-B2 | Cycloalkyfused indole, benzothiophene, benzofuran and idene derivatives | WYETH (US) | 2007-11-20 | — | — | US | disclosed |
| US-20060205759-A1 | Cycloalkylfused indole, benzothiophene, benzofuran and indene derivatives | WYETH (US) | 2006-09-14 | — | — | US | disclosed |
| WO-2006089053-A2 | CYCLOALKYLFUSED INDOLE, BENZOTHIOPHENE, BENZOFURAN AND INDENE DERIVATIVES | WYETH (US) | 2006-08-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12583818-B2 | Compound, preparation method thereof, and use thereof | TYRO3, TH, SRMS | SIRT1 4210/4885HTR1B 374/4885HTR1D 364/4885 |
| US-20060205759-A1 | Cycloalkylfused indole, benzothiophene, benzofuran and indene derivatives | TPH1, TPH2, HTR2C | SIRT1 389/4885HTR1B 19/4885HTR1D 18/4885 |
| US-20230142654-A1 | NOVEL COMPOUND, PREPARATION METHOD THEREOF, AND USE THEREOF | TYR, TYRO3, TH | SIRT1 4454/4885HTR1B 1311/4885HTR1D 2737/4885 |
| US-20080081910-A1 | CYCLOALKYLFUSED INDOLE, BENZOTHIOPHENE, BENZOFURAN AND INDENE DERIVATIVES | TPH1, TPH2, HTR2C | SIRT1 389/4885HTR1B 19/4885HTR1D 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.